Company is working on almost full capacity therefore revenue degrowth has happened YoY.
It got benefitted with excess inventory in Q1FY24 which is not present at the moment.
Growth is likely to be slow until migration happens from A) current Rifa-intermediate product to Rifapentine which will free up some capacity (it will lead to same revenues at 50% capacity as prices for the products are high while product’s requirment is low) coupled with B) New capex to be commissioned in FY25 end most likely.
But until then, don’t expect any growth this FY (especially since last year got the benefit of higher margins & stack up of inventory which was ultimately sold despite business running at full capacity)
| Subscribe To Our Free Newsletter |
